Knee Osteoarthritis Market expected to rise | Companies – Centrexion Therapeutics, Pfizer, Eli Lilly, Ampio Pharmaceuticals, Galapagos NV, Cytonics, Flexion Therapeutics, expected to drive market

Knee Osteoarthritis Market

The Knee Osteoarthritis market growth is driven by factors like increase in the prevalence of Knee Osteoarthritis, investments in research and development, entry of emerging therapies during the study period 2019-2032.

The Knee Osteoarthritis market report also offers comprehensive insights into the Knee Osteoarthritis market size, share, Knee Osteoarthritis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Knee Osteoarthritis market size growth forward. 

Some of the key highlights from the Knee Osteoarthritis Market Insights Report:

• Several key pharmaceutical companies, including Centrexion Therapeutics, Pfizer, Eli Lilly and Company, Ampio Pharmaceuticals, Galapagos NV, Cytonics, Flexion Therapeutics, and others, are developing novel products to improve the Knee Osteoarthritis treatment outlook. 
• The total Knee Osteoarthritis market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
• As per DelveInsight analysis, the Knee Osteoarthritis market is anticipated to witness growth at a considerable CAGR
• The Knee Osteoarthritis market is expected to strengthen as awareness of the disease increases and more effective interventions are being developed.

Strategise your business goals by understanding market dynamics @ Knee Osteoarthritis Market Landscape

Knee Osteoarthritis Overview 

The Knee Osteoarthritis Treatment Market is a crucial segment of the healthcare industry dedicated to addressing the growing prevalence of knee osteoarthritis, a debilitating condition affecting millions worldwide. Characterized by the gradual deterioration of knee joint cartilage, this condition leads to pain, stiffness, and reduced mobility, significantly impacting patients’ quality of life. The DelveInsight’s Knee Osteoarthritis market report gives a thorough understanding of the Knee Osteoarthritis by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

Knee Osteoarthritis Diagnosis

Knee osteoarthritis diagnosis is a crucial process aimed at identifying and understanding the extent of degeneration in the knee joint. Typically, this condition occurs as a result of the wear and tear of the cartilage, leading to pain, stiffness, and reduced mobility in the affected knee. This segment of the report covers the detailed diagnostic methods or tests for Knee Osteoarthritis.

Knee Osteoarthritis Treatment

Knee osteoarthritis treatment aims to alleviate pain, improve joint function, and enhance the overall quality of life for individuals suffering from this degenerative joint condition. The treatment approach typically involves a combination of non-pharmacological and pharmacological interventions. It covers the details of conventional and current medical therapies available in the Knee Osteoarthritis market for the treatment of the condition. It also provides Knee Osteoarthritis treatment algorithms and guidelines in the United States, Europe, and Japan.

Do you know the treatment paradigms for different countries? Download our Knee Osteoarthritis Market Sample Report

Recent Developmental Activities in the Knee Osteoarthritis Treatment Landscape

• Resiniferatoxin Gets Breakthrough Therapy Status for Knee Osteoarthritis Pain: The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to resiniferatoxin for the treatment of pain associated with osteoarthritis of the knee.
• On March 2023, Organogenesis announced a study of phase 3 clinical trials for Amniotic Suspension Allograft. The purpose of this study is to assess the effectiveness and safety of ASA (Acetylsalicylic Acid) in comparison to a placebo for treating the symptoms of knee osteoarthritis (OA).
• On March 2023, Medipost Co Ltd announced a study of phase 2 clinical trials for Active Control Group Sodium chloride. This clinical trial targets patients who have received a diagnosis of Kellgren-Lawrence (K&L) Grade 2 or 3 knee osteoarthritis through radiographic examination.
• On June 2023, Biosplice Therapeutics Inc announced a study of phase 3 clinical trials for Lorecivivint. This Phase 3 trial is a multi-center, randomized, double-blind, and placebo-controlled study. Its objective is to assess the safety and efficacy of lorecivivint when injected intra-articularly (IA) into the most painful knee joint of subjects with moderately to severely symptomatic osteoarthritis (OA). Each subject will receive a single dose of 0.07 mg of lorecivivint per 2 mL injection. The study will employ standard outcome measures to evaluate the effects of lorecivivint.

Knee Osteoarthritis Epidemiology Segmentation 

DelveInsight’s Knee Osteoarthritis market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Knee Osteoarthritis historical patient pools and forecasted Knee Osteoarthritis patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Knee Osteoarthritis Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

• Knee Osteoarthritis Prevalence 
• Age-Specific Knee Osteoarthritis Prevalence 
• Gender-Specific Knee Osteoarthritis Prevalence 
• Diagnosed and Treatable Cases of Knee Osteoarthritis

Visit for more @ Knee Osteoarthritis Epidemiological Insights

Knee Osteoarthritis Treatment Market 

The Knee Osteoarthritis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Knee Osteoarthritis market trends by analyzing the impact of current Knee Osteoarthritis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Knee Osteoarthritis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Knee Osteoarthritis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Knee Osteoarthritis market in 7MM is expected to witness a major change in the study period 2019-2032.

Knee Osteoarthritis Key Companies

• Centrexion Therapeutics
• Pfizer
• Eli Lilly and Company
• Ampio Pharmaceuticals
• Galapagos NV
• Cytonics
• Flexion Therapeutics

For more information, visit Knee Osteoarthritis Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Knee Osteoarthritis Market Report:

• 10 Years Forecast
• 7MM Coverage 
• Descriptive overview of Knee Osteoarthritis, causes, signs and symptoms, diagnosis, treatment
• Comprehensive insight into Knee Osteoarthritis epidemiology in the 7MM
• Knee Osteoarthritis marketed and emerging therapies 
• Knee Osteoarthritis companies
• Knee Osteoarthritis market drivers and barriers 

Key Questions Answered in the Knee Osteoarthritis Market Report 2032:

• What was the Knee Osteoarthritis market share distribution in 2019, and how would it appear in 2032?
• What is the total Knee Osteoarthritis market size and the market size by therapy across the 7MM for the study period (2019-32)?
• What are the important findings from 7MM, and which country will have the greatest Knee Osteoarthritis market size from 2019-32?
• During the study period (2019-2032), at what CAGR is the Knee Osteoarthritis market projected to expand at 7MM?

Table of Contents:

1 Knee Osteoarthritis Market Key Comprehensive Insights 

2 Knee Osteoarthritis Market Report Introduction

3 Competitive Intelligence Analysis for Knee Osteoarthritis

4 Knee Osteoarthritis Market Analysis Overview at a Glance

5 Executive Summary of Knee Osteoarthritis

6 Knee Osteoarthritis Epidemiology and Market Methodology

7 Knee Osteoarthritis Epidemiology and Patient Population

8 Knee Osteoarthritis Patient Journey

9 Knee Osteoarthritis Treatment Algorithm, Knee Osteoarthritis Current Treatment, and Medical Practices

10 Key Endpoints in Knee Osteoarthritis Clinical Trials

11 Knee Osteoarthritis Marketed Therapies 

12 Knee Osteoarthritis Emerging Therapies

13 Knee Osteoarthritis: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Knee Osteoarthritis

16 Knee Osteoarthritis Market Key Opinion Leaders Reviews

18 Knee Osteoarthritis Market Drivers

19 Knee Osteoarthritis Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Knee Osteoarthritis Epidemiology 2032

DelveInsight’s “Knee Osteoarthritis – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Knee Osteoarthritis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Knee Osteoarthritis Pipeline 2023

“Knee Osteoarthritis Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Knee Osteoarthritis market. A detailed picture of the Knee Osteoarthritis pipeline landscape is provided, which includes the disease overview and Knee Osteoarthritis treatment guidelines. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/